<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111381</url>
  </required_header>
  <id_info>
    <org_study_id>2000020245</org_study_id>
    <nct_id>NCT03111381</nct_id>
  </id_info>
  <brief_title>Toradol to Reduce Ureteroscopic Symptoms Trial</brief_title>
  <acronym>TRUST</acronym>
  <official_title>Toradol to Reduce Ureteroscopic Symptoms Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded randomized controlled clinical trial to assess the impact of intraoperative&#xD;
      Toradol on post-operative pain scores for patients undergoing ureteroscopy for urinary stone&#xD;
      management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated, single-center, prospective randomized clinical trial&#xD;
      evaluating the efficacy of intraoperative Ketorolac on post-operative pain in patients&#xD;
      undergoing ureteroscopy at Yale-New Haven Hospital.&#xD;
&#xD;
      The study population will include anyone between the age of 18-80 who is undergoing elective&#xD;
      ureteroscopy for management of stone disease without contraindication to ketorolac.&#xD;
&#xD;
      Patients who are being consented to undergo a ureteroscopy with the PI will be asked to&#xD;
      participate in this study. There is currently no consensus on standard of care regarding&#xD;
      intraoperative analgesia for ureteroscopy. There is wide variability in practice, some&#xD;
      clinicians choose to administer intraoperative analgesia while others rely only on the&#xD;
      sedation effects of general anesthesia. This study is being carried out to see if&#xD;
      administration of Ketorolac during ureteroscopy provides a post-operative benefit in pain&#xD;
      scores when compared to no treatment.&#xD;
&#xD;
      The intervention group in this study will receive a one-time dose of Ketorolac 30mg&#xD;
      intravenously after undergoing general anesthesia. Because participants will be under general&#xD;
      anesthesia, participants will not know if they received the medication. Following the&#xD;
      procedure, the intervention group may continue to use Ketorolac as needed to manage pain. The&#xD;
      only difference between the intervention group and the non-intervention group is the one time&#xD;
      dose of intraoperative ketorolac.&#xD;
&#xD;
      The FDA approves Ketorolac as a nonsteroidal anti-inflammatory drug (NSAID), indicated for&#xD;
      the short-term (up to 5 days in adults) management of moderately severe acute pain that&#xD;
      requires analgesia at the opioid level.&#xD;
&#xD;
      Following assessment of eligibility and documentation of consent to participate in the study,&#xD;
      participants will be randomized to receive intraoperative Ketorolac Tromethamine (ToradolÂ®)&#xD;
      or not. In the no-treatment group, participants will not receive a dose of intra-operative&#xD;
      Ketorolac. Pain will be managed in the standard way with post-operative Ketorolac as needed.&#xD;
      In the treatment group, participants will receive one dose of Ketorolac IV 30mg during the&#xD;
      procedure. Randomization will occur by the attending anesthesiologist.&#xD;
&#xD;
      For this trial, the investigators, surgical team, and patients will be blinded to the&#xD;
      administration of the agent, which is given as an IV Push of 30mg. For patients who are older&#xD;
      than 65 years or weight less than 50kg, the dose will be adjusted to 15mg to minimize the&#xD;
      risk of bleeding. The anesthesiologist will not be blinded as he/she will deliver the agent&#xD;
      and because the use of ketorolac may alter their usage of other intra-operative agents and&#xD;
      post-operative agents. The surgical team will be un-blinded post-operatively.&#xD;
&#xD;
      Following the procedure, participants will rate their pain using a visual pain assessment&#xD;
      scale at 1 hour postoperatively and at the time of discharge from the recovery room. Once the&#xD;
      patient is at home, the participant will fill out a validated survey that has questions&#xD;
      related to pain. This will be filled out once a day for a total of 7 days following the&#xD;
      procedure. In addition, the investigators will provide a medication utilization diary sheet&#xD;
      for the participant to record daily use of prescribed narcotic and other as needed over the&#xD;
      counter medications such as acetaminophen and ibuprofen.This will also be done daily for a&#xD;
      total of 7 days. The participant will be surveyed at a one-week postoperative visit using the&#xD;
      same assessment. All adverse drug reactions will be recorded from the time of administration&#xD;
      to initial follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pain</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Once the patient is at home, they will fill out a validated visual analog pain scale to rate their pain. This will be filled out once a day for a total of 7 days following the procedure.&#xD;
This is total morphine equivalent use. The range is 0 to infinity. Higher scores are equated to worse pain. The units are &quot;ME&quot; or morphine equivalents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complications</measure>
    <time_frame>6 weeks post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Urinary Lithiasis</condition>
  <condition>Kidney Diseases</condition>
  <condition>Kidney Stone</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Intervention Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toradol</intervention_name>
    <description>IV toradol</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing Ureteroscopy for kidney stone management between age 18-80.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide consent&#xD;
&#xD;
          -  Contraindications to Toradol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale Medial Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>May 26, 2021</results_first_submitted>
  <results_first_submitted_qc>November 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Lithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03111381/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03111381/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents&#xD;
Toradol: IV toradol</description>
        </group>
        <group group_id="P2">
          <title>Non-Intervention Group</title>
          <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents&#xD;
Toradol: IV toradol</description>
        </group>
        <group group_id="B2">
          <title>Non-Intervention Group</title>
          <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="147"/>
                    <measurement group_id="B2" value="33" spread="147"/>
                    <measurement group_id="B3" value="33" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Pain</title>
        <description>Once the patient is at home, they will fill out a validated visual analog pain scale to rate their pain. This will be filled out once a day for a total of 7 days following the procedure.&#xD;
This is total morphine equivalent use. The range is 0 to infinity. Higher scores are equated to worse pain. The units are &quot;ME&quot; or morphine equivalents.</description>
        <time_frame>up to 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents&#xD;
Toradol: IV toradol</description>
          </group>
          <group group_id="O2">
            <title>Non-Intervention Group</title>
            <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain</title>
          <description>Once the patient is at home, they will fill out a validated visual analog pain scale to rate their pain. This will be filled out once a day for a total of 7 days following the procedure.&#xD;
This is total morphine equivalent use. The range is 0 to infinity. Higher scores are equated to worse pain. The units are &quot;ME&quot; or morphine equivalents.</description>
          <units>milligram morphine equivalent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="14"/>
                    <measurement group_id="O2" value="30" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complications</title>
        <time_frame>6 weeks post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents&#xD;
Toradol: IV toradol</description>
          </group>
          <group group_id="O2">
            <title>Non-Intervention Group</title>
            <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded for 30 days from time of surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group</title>
          <description>The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents&#xD;
Toradol: IV toradol</description>
        </group>
        <group group_id="E2">
          <title>Non-Intervention Group</title>
          <description>In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamil Syed</name_or_title>
      <organization>Yale Urology</organization>
      <phone>2037852815</phone>
      <email>Jamil.syed@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

